Lantern Pharma gets FDA nod for LP-284 clinical trial in non-Hodgkin’s lymphoma

Lantern Pharma gets FDA nod for LP-284 clinical trial in non-Hodgkin’s lymphoma

Lantern Pharma Inc. (NASDAQ: LTRN), a trailblazer in artificial intelligence (AI) and machine learning (ML) for targeted cancer therapies, has received clearance from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application concerning LP-284. The cutting-edge drug is being developed for relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle […]

Lantern Pharma bags FDA orphan drug status for LP-184 in pancreatic cancer

Lantern Pharma bags FDA orphan drug status for LP-184 in pancreatic cancer

Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. According to the Texas-based clinical stage biopharma company, LP-184 is a next generation alkylating agent that selectively damages DNA in cancer cells that over-express certain biomarkers or […]